Compare EBF & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | IPSC |
|---|---|---|
| Founded | 1909 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.5M | 441.9M |
| IPO Year | 1994 | 2021 |
| Metric | EBF | IPSC |
|---|---|---|
| Price | $21.49 | $2.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 160.1K | ★ 1.9M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | 7.79 | ★ 91.30 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $55.10 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $16.30 | $0.44 |
| 52 Week High | $22.36 | $2.97 |
| Indicator | EBF | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 56.52 |
| Support Level | $19.92 | $2.13 |
| Resistance Level | $22.36 | $2.45 |
| Average True Range (ATR) | 0.58 | 0.18 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 77.72 | 68.00 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others. The company's single reportable segment : Print derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.